The Young and the Resistant: HIV-Infected Adolescents at the Time of Transfer to Adult Care

Dimitri Van der Linden; Normand Lapointe; Fatima Kakkar; Doris G Ransy; Alena Motorina; François Maurice; Hugo Soudeyns; Valérie Lamarre

doi:10.1093/jpids/pis106

The Young and the Resistant: HIV-Infected Adolescents at the Time of Transfer to Adult Care

J Pediatric Infect Dis Soc. 2013 Dec;2(4):382-5. doi: 10.1093/jpids/pis106. Epub 2012 Dec 19.

Authors

Dimitri Van der Linden¹, Normand Lapointe², Fatima Kakkar³, Doris G Ransy⁴, Alena Motorina⁴, François Maurice⁵, Hugo Soudeyns⁶, Valérie Lamarre⁷

Affiliations

¹ Department of Pediatrics, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, and Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium Infectious Diseases Service.
² Centre Maternel et Infantile sur le SIDA, CHU Sainte-Justine Departments of Pediatrics, and.
³ Infectious Diseases Service Centre Maternel et Infantile sur le SIDA, CHU Sainte-Justine Departments of Pediatrics, and.
⁴ Microbiology and Immunology, Faculty of Medicine, Université de Montréal Unité d'Immunopathologie Virale, Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada.
⁵ Centre Maternel et Infantile sur le SIDA, CHU Sainte-Justine.
⁶ Departments of Pediatrics, and Microbiology and Immunology, Faculty of Medicine, Université de Montréal Unité d'Immunopathologie Virale, Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada.
⁷ Infectious Diseases Service Centre Maternel et Infantile sur le SIDA, CHU Sainte-Justine Departments of Pediatrics, and valerie.lamarre@umontreal.ca.

PMID: 26619501
DOI: 10.1093/jpids/pis106

Abstract

Combined antiretroviral therapy allows children with human immunodeficiency virus (HIV) to reach adulthood. We studied 45 adolescents at the time of transfer to adult care. Despite universal healthcare access, over two-thirds of the adolescents were failing treatment, which was manifested by detectable HIV-1 viral load, CD4 counts <200 cells/ mm(3), and/or triple-class drug resistance.